Literature DB >> 11437406

Cellular mechanisms of bone resorption in breast carcinoma.

N C Hunt1, Y Fujikawa, A Sabokbar, I Itonaga, A Harris, N A Athanasou.   

Abstract

The cellular mechanisms that account for the increase in osteoclast numbers and bone resorption in skeletal breast cancer metastasis are unclear. Osteoclasts are marrow-derived cells which form by fusion of mononuclear phagocyte precursors that circulate in the monocyte fraction. In this study we have determined whether circulating osteoclast precursors are increased in number or have an increased sensitivity to humoral factors for osteoclastogenesis in breast cancer patients with skeletal metastases (+/- hypercalcaemia) compared to patients with primary breast cancer and age-matched normal controls. Monocytes were isolated and cocultured with UMR 106 osteoblastic cells in the presence of 1,25 dihydroxyvitamin D3[1,25(OH)2D3] and human macrophage colony stimulating factor (M-CSF) on coverslips and dentine slices. Limiting dilution experiments showed that there was no increase in the number of circulating osteoclast precursors in breast cancer patients with skeletal metastases (+/- hypercalcaemia) compared to controls. Osteoclast precursors in these patients also did not exhibit increased sensitivity to 1,25(OH)2D3or M-CSF in terms of osteoclast formation. The addition of parathyroid hormone-related protein and interleukin-6 did not increase osteoclast formation. The addition of the supernatant of cultured breast cancer cell lines (MCF-7 and MDA-MB-435), however, significantly increased monocyte-osteoclast formation in a dose-dependent fashion. These results indicate that the increase in osteoclast formation in breast cancer is not due to an increase in the number/nature of circulating osteoclast precursors. They also suggest that tumour cells promote osteoclast formation in the bone microenvironment by secreting soluble osteoclastogenic factor(s). Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11437406      PMCID: PMC2363911          DOI: 10.1054/bjoc.2001.1856

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells.

Authors:  N Udagawa; N Takahashi; T Akatsu; H Tanaka; T Sasaki; T Nishihara; T Koga; T J Martin; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

2.  A human cell line from a pleural effusion derived from a breast carcinoma.

Authors:  H D Soule; J Vazguez; A Long; S Albert; M Brennan
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

3.  Resorption of dentine by isolated osteoclasts in vitro.

Authors:  A Boyde; N N Ali; S J Jones
Journal:  Br Dent J       Date:  1984-03-24       Impact factor: 1.626

4.  Characterization of osteoclast precursors in human blood.

Authors:  V Shalhoub; G Elliott; L Chiu; R Manoukian; M Kelley; N Hawkins; E Davy; G Shimamoto; J Beck; S A Kaufman; G Van; S Scully; M Qi; M Grisanti; C Dunstan; W J Boyle; D L Lacey
Journal:  Br J Haematol       Date:  2000-11       Impact factor: 6.998

5.  Monoclonal antibodies to osteoclastomas (giant cell bone tumors): definition of osteoclast-specific cellular antigens.

Authors:  M A Horton; D Lewis; K McNulty; J A Pringle; T J Chambers
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

6.  Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice.

Authors:  J E Price; A Polyzos; R D Zhang; L M Daniels
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

7.  Macrophage content of spontaneous metastases at different stages of growth.

Authors:  P J Bugelski; S P Corwin; S M North; R L Kirsh; G L Nicolson; G Poste
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701

8.  Osteoclasts are required for bone tumors to grow and destroy bone.

Authors:  D R Clohisy; M L Ramnaraine
Journal:  J Orthop Res       Date:  1998-11       Impact factor: 3.494

9.  RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis.

Authors:  N Nakagawa; M Kinosaki; K Yamaguchi; N Shima; H Yasuda; K Yano; T Morinaga; K Higashio
Journal:  Biochem Biophys Res Commun       Date:  1998-12-18       Impact factor: 3.575

10.  Functional properties of hormonally responsive cultured normal and malignant rat osteoblastic cells.

Authors:  N C Partridge; D Alcorn; V P Michelangeli; B E Kemp; G B Ryan; T J Martin
Journal:  Endocrinology       Date:  1981-01       Impact factor: 4.736

View more
  4 in total

Review 1.  The macrophage growth factor CSF-1 in mammary gland development and tumor progression.

Authors:  Elaine Y Lin; Valerie Gouon-Evans; Andrew V Nguyen; Jeffrey W Pollard
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

2.  Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathway.

Authors:  Simone Reuter; Sahdeo Prasad; Kanokkarn Phromnoi; Ramaswamy Kannappan; Vivek R Yadav; Bharat B Aggarwal
Journal:  Mol Cancer Res       Date:  2010-09-08       Impact factor: 5.852

3.  SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.

Authors:  Lesley J Murray; Tinya J Abrams; Kelly R Long; Theresa J Ngai; Lisa M Olson; Weiru Hong; Paul K Keast; Jacqueline A Brassard; Anne Marie O'Farrell; Julie M Cherrington; Nancy K Pryer
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

4.  A tale of mice and (wo)men: development of and insights from an "all human" animal model of breast cancer metastasis to bone.

Authors:  Michael Rosenblatt
Journal:  Trans Am Clin Climatol Assoc       Date:  2012
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.